Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc. (Delaware)

Grade Last Price % Change Price Change
grade D 0.56 -3.45% -0.02
ATNM closed down 4.92 percent on Monday, March 18, 2019, on 52 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
8 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical ATNM trend table...

Date Alert Name Type % Chg
Mar 18 Fell Below 200 DMA Bearish -3.45%
Mar 18 Fell Below 20 DMA Bearish -3.45%
Mar 18 Earnings Movers Other -3.45%
Mar 18 Inside Day Range Contraction -3.45%
Mar 15 Crossed Above 200 DMA Bullish -8.20%
Mar 15 Crossed Above 20 DMA Bullish -8.20%
Mar 15 Earnings Movers Other -8.20%
Mar 14 200 DMA Resistance Bearish -1.89%
Mar 14 20 DMA Resistance Bearish -1.89%
Mar 14 Oversold Stochastic Weakness -1.89%

Older signals for ATNM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.
Chemistry Biopharmaceutical Cancer Physical Sciences Alpha Natural Sciences Immunology Chemical Elements Antibodies Stem Cells Acute Myeloid Leukemia Monoclonal Antibody Platform Technology Transplantation Actinides
Is ATNM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 15 Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
Mar 15 Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
Mar 7 What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?
Feb 25 4 Healthcare Stocks Looking To Kick Off A Strong Week
Feb 25 Actinium's Iomab-B shows positive action in late-stage study
Feb 25 Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
Feb 22 The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
Feb 21 Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
Feb 15 Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications
Feb 12 Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
See more ATNM news...
Indicators
Indicator Value
52 Week High 0.865
52 Week Low 0.33
Average Volume 780,016
200-Day Moving Average 0.5905
50-Day Moving Average 0.5421
20-Day Moving Average 0.595
10-Day Moving Average 0.5812
Average True Range 0.0464
ADX 24.18
+DI 19.7016
-DI 13.2728
Chandelier Exit (Long, 3 ATRs ) 0.5708
Chandelier Exit (Short, 3 ATRs ) 0.6692
Upper Bollinger Band 0.6463
Lower Bollinger Band 0.5437
Percent B (%b) 0.35
BandWidth 17.243698
MACD Line 0.0088
MACD Signal Line 0.0134
MACD Histogram -0.0046
Fundamentals Value
Market Cap 46.41 Million
Num Shares 80 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -1.12
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.65
Resistance 3 (R3) 0.66 0.64 0.64
Resistance 2 (R2) 0.64 0.62 0.64 0.64
Resistance 1 (R1) 0.61 0.61 0.60 0.60 0.63
Pivot Point 0.59 0.59 0.59 0.59 0.59
Support 1 (S1) 0.56 0.57 0.55 0.56 0.53
Support 2 (S2) 0.54 0.56 0.54 0.52
Support 3 (S3) 0.51 0.54 0.52
Support 4 (S4) 0.51